Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Dr. Kotini Foundation
Street 1: D.No. 1-145, Rajamapalem, Dondapudi post, Gopalapuram Mandal, west Godavari Dist, Andhra Pradesh
Street 2:
City: Rajampalem village
Province:
Post Code: 534318
Country: India
Phone: +91-7673919963
Organization Email: suresh.drkotinifoundation@gmail.com
Web Site: http://www.drkotinifoundation.com
Other Online Presence:

Focal Point Contact Information

Salutation: Dr
First Name: SURESH BABU
Last Name: KOTINI
Title: Founder & President
Email: suresh.drkotinifoundation@gmail.com
Phone:  

Alternate Focal Point Contact Information

Salutation: Ms
First Name: SATYAVATHI
Last Name: KOTINI
Title:  
Email: kotini.satyavathi@gmail.com
Phone:  

General Information

Board Constituency: None
Is your organization legally registered in your country: Yes
If yes, please enter your registration number: 10/2013
Organization Type - Primary: Non-Governmental Organization
Organization Type - Secondary: Other Non-Governmental Organization (NGO)
Organization Description:
1. Education, Promotion of science & research, Health care programmes etc.

2. Mycobacterium tuberculosis (Mtb) is a major human pathogenic bacteria and the causative agent of Tuberculosis (TB) disease. In the most cases, TB is treatable and curable. However, people with TB can die if they do not get proper treatment. Sometimes drug-resistant TB occurs when bacteria becomes resistant to the drugs used to treat TB. This means that the drug can no longer kill the bacteria. TB is highly infectious disease, declared a global health emergency by the World Health Organization (WHO) and is still the second leading killer in the world. According to WHO, in 2017, approx. 11 million (1.1 core) people infected/fell ill with TB disease, and approx. 2 million (20 lakhs) people died from TB disease worldwide and India is the leading the count. This means that, approx. 5,000-6,000 people die each day due to TB disease. Unfortunately, the lack of adherence to prescribed treatment procedure and inefficient healthcare structure have contributed to the development of multidrug-resistant TB (MDR-TB), defined as resistance to at least isoniazid and rifampicin, two front-line drugs used for treatment of TB that requires at least 20 months of treatment of second-line drugs comprised of capreomycin, kanamycin, amikacin and fluoroquinolones; these are more toxic and less efficient, which cure rates in the range of 60-70%.

3. In patients affected by extensively drug-resistant (XDR)-TB, the chances of successful treatment are quite low, underpinning the need for urgent discovery of novel compounds with activity against Mtb strains resistant to second-line drugs and search for new antitubercular drugs is a priority so as to overcome the problem of drug resistance and to finally eradicate TB disease.In addition to that conducting TB care and control and disease spreading awareness programmes etc.
 
Do you know about the UNHLM declaration: No

Specializations / Areas of Work

Research and Development
Technical Assistance

Other Organization Information

Total number of staff in your organization: 1 - 5
Number of full-time staff who are directly involved with TB: 1 - 5
Number of part-time staff who are directly involved with TB: Unknown
Number of volunteers who are directly involved with TB: 1 - 5
 
How did you hear about the Stop TB Partnership: Internet search
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Involvement in Stop TB Working Groups
 
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: No
Please tell us how your organization is contributing to your country's national TB control plan:
we started working recently on these issues
 

Geographical Reach

Which country is your headquarters located in: India
Which countries do you do operate in:
(This includes countries you are conducting activities in)
India

Contribution

Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

Drug-Resistant TB:
Mycobacterium tuberculosis (Mtb) is a major human pathogenic bacteria and the causative agent of Tuberculosis (TB) disease. In the most cases, TB is treatable and curable. However, people with TB can die if they do not get proper treatment. Sometimes drug-resistant TB occurs when bacteria becomes resistant to the drugs used to treat TB. This means that the drug can no longer kill the bacteria. TB is highly infectious disease, declared a global health emergency by the World Health Organization (WHO) and is still the second leading killer in the world. According to WHO, in 2017, approx. 11 million (1.1 core) people infected/fell ill with TB disease, and approx. 2 million (20 lakhs) people died from TB disease worldwide and India is the leading the count. This means that, approx. 5,000-6,000 people die each day due to TB disease. Unfortunately, the lack of adherence to prescribed treatment procedure and inefficient healthcare structure have contributed to the development of multidrug-resistant TB (MDR-TB), defined as resistance to at least isoniazid and rifampicin, two front-line drugs used for treatment of TB that requires at least 20 months of treatment of second-line drugs comprised of capreomycin, kanamycin, amikacin and fluoroquinolones; these are more toxic and less efficient, which cure rates in the range of 60-70%. In patients affected by extensively drug-resistant (XDR)-TB, the chances of successful treatment are quite low, underpinning the need for urgent discovery of novel compounds with activity against Mtb strains resistant to second-line drugs and search for new antitubercular drugs is a priority so as to overcome the problem of drug resistance and to finally eradicate TB disease.

Fundamental Research:
Mycobacterium tuberculosis (Mtb) is a major human pathogenic bacteria and the causative agent of Tuberculosis (TB) disease. In the most cases, TB is treatable and curable. However, people with TB can die if they do not get proper treatment. Sometimes drug-resistant TB occurs when bacteria becomes resistant to the drugs used to treat TB. This means that the drug can no longer kill the bacteria. TB is highly infectious disease, declared a global health emergency by the World Health Organization (WHO) and is still the second leading killer in the world. According to WHO, in 2017, approx. 11 million (1.1 core) people infected/fell ill with TB disease, and approx. 2 million (20 lakhs) people died from TB disease worldwide and India is the leading the count. This means that, approx. 5,000-6,000 people die each day due to TB disease. Unfortunately, the lack of adherence to prescribed treatment procedure and inefficient healthcare structure have contributed to the development of multidrug-resistant TB (MDR-TB), defined as resistance to at least isoniazid and rifampicin, two front-line drugs used for treatment of TB that requires at least 20 months of treatment of second-line drugs comprised of capreomycin, kanamycin, amikacin and fluoroquinolones; these are more toxic and less efficient, which cure rates in the range of 60-70%. In patients affected by extensively drug-resistant (XDR)-TB, the chances of successful treatment are quite low, underpinning the need for urgent discovery of novel compounds with activity against Mtb strains resistant to second-line drugs and search for new antitubercular drugs is a priority so as to overcome the problem of drug resistance and to finally eradicate TB disease.

Research:
Mycobacterium tuberculosis (Mtb) is a major human pathogenic bacteria and the causative agent of Tuberculosis (TB) disease. In the most cases, TB is treatable and curable. However, people with TB can die if they do not get proper treatment. Sometimes drug-resistant TB occurs when bacteria becomes resistant to the drugs used to treat TB. This means that the drug can no longer kill the bacteria. TB is highly infectious disease, declared a global health emergency by the World Health Organization (WHO) and is still the second leading killer in the world. According to WHO, in 2017, approx. 11 million (1.1 core) people infected/fell ill with TB disease, and approx. 2 million (20 lakhs) people died from TB disease worldwide and India is the leading the count. This means that, approx. 5,000-6,000 people die each day due to TB disease. Unfortunately, the lack of adherence to prescribed treatment procedure and inefficient healthcare structure have contributed to the development of multidrug-resistant TB (MDR-TB), defined as resistance to at least isoniazid and rifampicin, two front-line drugs used for treatment of TB that requires at least 20 months of treatment of second-line drugs comprised of capreomycin, kanamycin, amikacin and fluoroquinolones; these are more toxic and less efficient, which cure rates in the range of 60-70%. In patients affected by extensively drug-resistant (XDR)-TB, the chances of successful treatment are quite low, underpinning the need for urgent discovery of novel compounds with activity against Mtb strains resistant to second-line drugs and search for new antitubercular drugs is a priority so as to overcome the problem of drug resistance and to finally eradicate TB disease.

Declaration

Declaration of interests:
Mycobacterium tuberculosis (Mtb) is a major human pathogenic bacteria and the causative agent of Tuberculosis (TB) disease. In the most cases, TB is treatable and curable. However, people with TB can die if they do not get proper treatment. Sometimes drug-resistant TB occurs when bacteria becomes resistant to the drugs used to treat TB. This means that the drug can no longer kill the bacteria. TB is highly infectious disease, declared a global health emergency by the World Health Organization (WHO) and is still the second leading killer in the world. According to WHO, in 2017, approx. 11 million (1.1 core) people infected/fell ill with TB disease, and approx. 2 million (20 lakhs) people died from TB disease worldwide and India is the leading the count. This means that, approx. 5,000-6,000 people die each day due to TB disease. Unfortunately, the lack of adherence to prescribed treatment procedure and inefficient healthcare structure have contributed to the development of multidrug-resistant TB (MDR-TB), defined as resistance to at least isoniazid and rifampicin, two front-line drugs used for treatment of TB that requires at least 20 months of treatment of second-line drugs comprised of capreomycin, kanamycin, amikacin and fluoroquinolones; these are more toxic and less efficient, which cure rates in the range of 60-70%. In patients affected by extensively drug-resistant (XDR)-TB, the chances of successful treatment are quite low, underpinning the need for urgent discovery of novel compounds with activity against Mtb strains resistant to second-line drugs and search for new antitubercular drugs is a priority so as to overcome the problem of drug resistance and to finally eradicate TB disease.In addition to that conducting TB care and control and disease spreading awareness programmes etc.

Application date: December 29, 2018
Last updated: December 29, 2018